CS
ABEO icon

Credit Suisse’s Abeona Therapeutics ABEO Stock Holding History

Credit Suisse’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-687
Closed -$27K – 4265
2020
Q4 		$27K Buy
+687
New +$23.4K ﹤0.01% 4290
2019
Q4 		– Sell
-1,180
Closed -$67K – 4134
2019
Q3 		$67K Sell
1,180
-138
-10% -$10.3K ﹤0.01% 4007
2019
Q2 		$157K Buy
1,318
+201
+18% +$33.7K ﹤0.01% 3888
2019
Q1 		$205K Sell
1,117
-374
-25% -$66.9K ﹤0.01% 3754
2018
Q4 		$265K Buy
1,491
+203
+16% +$44.3K ﹤0.01% 3565
2018
Q3 		$412K Sell
1,288
-157
-11% -$55.7K ﹤0.01% 3396
2018
Q2 		$579K Buy
1,445
+52
+4% +$22.7K ﹤0.01% 3351
2018
Q1 		$499K Buy
1,393
+59
+4% +$21.9K ﹤0.01% 3368
2017
Q4 		$529K Buy
1,334
+376
+39% +$155K ﹤0.01% 3408
2017
Q3 		$408K Buy
+958
New +$257K ﹤0.01% 3600
2016
Q3 		– Sell
-574
Closed -$33K – 4066
2016
Q2 		$33K Buy
+574
New +$39.2K ﹤0.01% 4169
2015
Q4 		– Sell
-513
Closed -$52K – 4195
2015
Q3 		$52K Sell
513
-1,801
-78% -$239K ﹤0.01% 4173
2015
Q2 		$293K Buy
+2,314
New +$348K ﹤0.01% 4027

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's ABEO Position: Q1 2021 in Review

Credit Suisse sold out of Abeona Therapeutics (ABEO) in Q1 2021, closing a stake of 687 shares — an estimated $27K sold.

Credit Suisse first reported a position in ABEO in Q2 2015 and held it in 13 quarters. The position peaked at $579K in Q2 2018. 75 funds tracked by Wall St. Rank hold ABEO as of Q1 2021.

  • Credit Suisse reported no remaining Abeona Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Credit Suisse sold 687 Abeona Therapeutics shares in Q1 2021, an estimated $27K.
  • Credit Suisse first reported a position in Abeona Therapeutics in Q2 2015 and held it in 13 quarters.
  • Credit Suisse's Abeona Therapeutics position peaked at $579K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.